Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors
Louis M. Scott, … , Andrew D. Dick, Sofia Theodoropoulou
Louis M. Scott, … , Andrew D. Dick, Sofia Theodoropoulou
Published April 22, 2021
Citation Information: JCI Insight. 2021;6(8):e129429. https://doi.org/10.1172/jci.insight.129429.
View: Text | PDF
Research Article Metabolism Ophthalmology

Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors

  • Text
  • PDF
Abstract

It remains unresolved how retinal pigment epithelial cell metabolism is regulated following immune activation to maintain retinal homeostasis and retinal function. We exposed retinal pigment epithelium (RPE) to several stress signals, particularly Toll-like receptor stimulation, and uncovered an ability of RPE to adapt their metabolic preference on aerobic glycolysis or oxidative glucose metabolism in response to different immune stimuli. We have identified interleukin-33 (IL-33) as a key metabolic checkpoint that antagonizes the Warburg effect to ensure the functional stability of the RPE. The identification of IL-33 as a key regulator of mitochondrial metabolism suggests roles for the cytokine that go beyond its extracellular “alarmin” activities. IL-33 exerts control over mitochondrial respiration in RPE by facilitating oxidative pyruvate catabolism. We have also revealed that in the absence of IL-33, mitochondrial function declined and resultant bioenergetic switching was aligned with altered mitochondrial morphology. Our data not only shed new light on the molecular pathway of activation of mitochondrial respiration in RPE in response to immune stressors but also uncover a potentially novel role of nuclear intrinsic IL-33 as a metabolic checkpoint regulator.

Authors

Louis M. Scott, Emma E. Vincent, Natalie Hudson, Chris Neal, Nicholas Jones, Ed C. Lavelle, Matthew Campbell, Andrew P. Halestrap, Andrew D. Dick, Sofia Theodoropoulou

×

Figure 6

Role of nuclear IL-33 in mitochondrial metabolism.

Options: View larger image (or click on image) Download as PowerPoint
Role of nuclear IL-33 in mitochondrial metabolism.
(A) Gene expression o...
(A) Gene expression of IL33 following transfection of ARPE-19 with either an IL-33 activation plasmid or scrambled gRNA activation plasmid (n = 3). (B) Representative immunoblot of IL-33 expression in ARPE-19 transfected with either an IL-33 activation plasmid or scrambled gRNA activation plasmid (n = 3). (C) ARPE-19 were transfected with either an IL-33 activation plasmid or scrambled guide RNA (gRNA) activation plasmid; cell lysates were split into nuclear or cytoplasmic fractions, and Western blotting was used to determine the subcellular location of IL-33 (n = 2). (D) Mitochondrial stress test following transfection of ARPE-19 with either an IL-33 activation plasmid or scrambled gRNA activation plasmid; XF injections were oligomycin (1 μM), FCCP (0.5 μM), and rotenone/antimycin A (1 μM) (n = 3). (E) Parameters calculated from D (as detailed in Methods) (n = 3). (F) Glycolysis stress test following transfection of ARPE-19 with either an IL-33 activation plasmid or scrambled gRNA activation plasmid; XF injections were oligomycin (1 μM), FCCP (0.5 μM), and rotenone/antimycin A (1 μM) (n = 3). (G) Parameters calculated from F (as detailed in Methods) (n = 3). (H) ARPE-19 were transfected with either an IL-33 activation plasmid or scrambled gRNA activation plasmid; RT-PCR was used to determine the relative gene expression of targets involved in glycolysis or the TCA cycle (n = 3). (I and J) ARPE-19 were transfected with either an IL-33 activation plasmid or scrambled gRNA activation plasmid; expression of PKM2, GLUT1, and PC (n = 3) was determined by immunoblot. (K) Representative transmission electron microscopy of ARPE-19 cells transfected with an IL-33 activation plasmid or scrambled gRNA activation plasmid. Original magnification, ×4500. Data are expressed as means ± SD from at least 3 independent experiments. (D–G) Represent the biological repeats from 3 independent experiments (n = 3); each biological repeat is the mean of 2 technical repeats (2 seahorse wells per experiment). (C) Represents 2 independent immunoblots. One-way ANOVA with Dunnett’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts